Journal: Oligonucleotides

Article Title: Therapeutic Applications of DNA and RNA Aptamers

doi: 10.1089/oli.2009.0199

Figure Lengend Snippet: Aptamers in the Clinical Pipeline

Article Snippet: For the purpose of this review, special focus will be placed on aptamers that have entered the clinical pipeline or demonstrate exceptional therapeutic potential based on preclinical studies ( ). table ft1 table-wrap mode="anchored" t5 Table 1. caption a7 Aptamer, target Company Disease(s) Stage of clinical development Pegaptanib (Macugen), VEGF-165 Eyetech Pharmaceuticals/ Pfizer AMD, diabetic retinopathy FDA-approved AMD 2004; Phase II for diabetic retinopathy: improved vision, decreased edema REG-1 (RB006/RB007), Factor IXa Regado Biosciences PCI, CABG Phase I: Reversible anti coagulation; Phase II trial completed (results not released) AS1411, Nucleolin Antisoma RCC, AML Phase I: Tumor regression; Phase II underway NU172, Thrombin Nuvelo/Archemix PCI, CABG Phase I: No adverse safety profile; Phase II planned ARC1779, von Willebrand factor Archemix TMA, TTP, CEA Phase I: No adverse effects in healthy patients; Phase II underway ARC183, Thrombin Archemix CABG Phase I: Suboptimal dose profile; withdrawn Open in a separate window Abbreviations: AMD, age-related macular degeneration; PCI, percutaneous coronary intervention; CABG, coronary artery bypass graft; RCC, renal cell carcinoma; AML, acute myeloid leukemia; TMA, thrombotic microangiopathies; TTP, thrombocytopenic purpura; CEA, carotid endarterectomy.

Techniques: Coagulation

Journal: Oligonucleotides

Article Title: Therapeutic Applications of DNA and RNA Aptamers

doi: 10.1089/oli.2009.0199

Figure Lengend Snippet: Regulatable aptamer, REG-1. A schematic of the predicted secondary structure of REG-1 aptamer is shown in the left panel. The antidote oligo (middle), is complementary to the 3′ end of the REG-1 aptamer and, when combined with the REG-1 aptamer, promotes unfolding of the aptamer, thus abrogating aptamer interaction with the target, factor IXa. Adapted from Rusconi et al. (2002).

Article Snippet: For the purpose of this review, special focus will be placed on aptamers that have entered the clinical pipeline or demonstrate exceptional therapeutic potential based on preclinical studies ( ). table ft1 table-wrap mode="anchored" t5 Table 1. caption a7 Aptamer, target Company Disease(s) Stage of clinical development Pegaptanib (Macugen), VEGF-165 Eyetech Pharmaceuticals/ Pfizer AMD, diabetic retinopathy FDA-approved AMD 2004; Phase II for diabetic retinopathy: improved vision, decreased edema REG-1 (RB006/RB007), Factor IXa Regado Biosciences PCI, CABG Phase I: Reversible anti coagulation; Phase II trial completed (results not released) AS1411, Nucleolin Antisoma RCC, AML Phase I: Tumor regression; Phase II underway NU172, Thrombin Nuvelo/Archemix PCI, CABG Phase I: No adverse safety profile; Phase II planned ARC1779, von Willebrand factor Archemix TMA, TTP, CEA Phase I: No adverse effects in healthy patients; Phase II underway ARC183, Thrombin Archemix CABG Phase I: Suboptimal dose profile; withdrawn Open in a separate window Abbreviations: AMD, age-related macular degeneration; PCI, percutaneous coronary intervention; CABG, coronary artery bypass graft; RCC, renal cell carcinoma; AML, acute myeloid leukemia; TMA, thrombotic microangiopathies; TTP, thrombocytopenic purpura; CEA, carotid endarterectomy.

Techniques:

Journal: Materials

Article Title: Functional Fibronectin Adsorption on Aptamer-Doped Chitosan Modulates Cell Morphology by Integrin-Mediated Pathway

doi: 10.3390/ma12050812

Figure Lengend Snippet: Diagram representing the rationale for the aptamer-coated scaffold to retain fibronectin in a suitable geometric conformation. Un-coated scaffold (CH) adsorbs fibronectin from the surrounding milieu, mostly inducing the masking of cell binding domains. Aptamers specifically lead the adsorption of fibronectin (sFBN-CH) and enrich scaffold with docking points for effective cell adhesion. The 3D rendering of the anti-fibronectin aptamer is a courtesy of Base Pair Biotechnologies (Pearland, TX, USA).

Article Snippet: Excess of reducing agent was then removed with a chromatographic column (mini Quick Spin Oligo Columns, Roche Life Science, Branford, CT, USA) and aptamers were finally diluted at their working concentration in aptamer folding buffer (Base Pair Biotechnologies) [ , ].

Techniques: Binding Assay, Adsorption

Journal: Materials

Article Title: Functional Fibronectin Adsorption on Aptamer-Doped Chitosan Modulates Cell Morphology by Integrin-Mediated Pathway

doi: 10.3390/ma12050812

Figure Lengend Snippet: HeLa cells spreading on sFBN-CH. ( a ) Histograms showing the number of spread cells on CH and sFBN-CH after 1, 3 and 4 days of culture. ( b ) Histograms the number of spread cells on CH and sFBN-CH enriched with increasing doses of aptamers after 1, 3 and 4 days of culture. ( c ) The trend of cell spread rate on chitosan discs implemented with increasing aptamer doses. ( d ) The trend of angular coefficients derived from cell spread on chitosan discs implemented with increasing aptamer doses (* = p < 0.05).

Article Snippet: Excess of reducing agent was then removed with a chromatographic column (mini Quick Spin Oligo Columns, Roche Life Science, Branford, CT, USA) and aptamers were finally diluted at their working concentration in aptamer folding buffer (Base Pair Biotechnologies) [ , ].

Techniques: Derivative Assay

Journal: Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology

Article Title: The EARLY DETECTION RESEARCH NETWORK: A National Infrastructure to Support the Discovery, Development and Validation of Cancer Biomarkers

doi: 10.1158/1055-9965.EPI-20-0237

Figure Lengend Snippet: Tests in Clinical Laboratory Improvement Amendments (CLIA) Laboratories

Article Snippet: Celera Aptamer-based markers Detection of lung cancer William Rom, M.D., M.P.H.

Techniques: Biomarker Assay, Expressing, Methylation, Diagnostic Assay, Multiplex Assay, Blocking Assay